As cholinesterase inhibitors are the current treatment for Alzheimer’s disease, terpene-derived metabolites will have the potential to be involved in the future drug development for Alzheimer’s disease. The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.